Source comparison
Thymosin Alpha-1 Science Explained: Clinical Research Comparison
The table below compares Thymosin Alpha-1 performance across documented clinical applications, highlighting response rates, trial designs, and practical assessment. Chronic Hepatitis B Phase III RCT, 234 patients, 52 weeks HBeAg seroconversion 36% vs 19% place
This comparison does not assign a generated winner or score.
- The table below compares Thymosin Alpha-1 performance across documented clinical applications, highlighting response rates, trial designs, and practical assessment.
- Chronic Hepatitis B
- Phase III RCT, 234 patients, 52 weeks
- HBeAg seroconversion
- 36% vs 19% placebo
- Comparable efficacy to interferon-alpha without severe adverse events. Practical alternative for interferon-intolerant patients
- Hepatocellular Carcinoma (Adjuvant)
- Meta-analysis, 23 trials, 3,736 patients
- 24-month overall survival
- Hazard ratio 0.71 (29% mortality reduction)
- Greatest benefit in immunosuppressed subgroups (CD4+ <400 cells/μL). Effect diminishes in immune-competent cohorts
- Severe Sepsis
- Multi-center observational, 361 ICU patients
- 28-day mortality
- 31% vs 44% standard care
- Maintains monocyte HLA-DR expression during septic immunosuppression. Mechanistic benefit demonstrated, needs Phase III confirmation
- Non-Small Cell Lung Cancer
- Phase II trial, 88 patients with chemo
- Progression-free survival at 12 months
- 41% vs 28% chemo alone
- Adjuvant immune support during myelosuppressive therapy. Does not replace primary treatment but may extend response duration